Immunosenescence and hurdles in the clinical management of older HIV-patients

M Ripa, S Chiappetta, G Tambussi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

People living with HIV (PLWH) who are treated with effective highly active antiretroviral therapy (HAART) have a similar life expectancy to the general population. Moreover, an increasing proportion of new HIV diagnoses are made in people older than 50 y. The number of older HIV-infected patients is thus constantly growing and it is expected that by 2030 around 70% of PLWH will be more than 50 y old. On the other hand, HIV infection itself is responsible for accelerated immunosenescence, a progressive decline of immune system function in both the adaptive and the innate arm, which impairs the ability of an individual to respond to infections and to give rise to long-term immunity; furthermore, older patients tend to have a worse immunological response to HAART. In this review we focus on the pathogenesis of HIV-induced immunosenescence and on the clinical management of older HIV-infected patients. © 2017 Taylor & Francis
Original languageEnglish
Pages (from-to)508-528
Number of pages21
JournalVirulence
Volume8
Issue number5
DOIs
Publication statusPublished - 2017

Fingerprint

HIV
Highly Active Antiretroviral Therapy
Life Expectancy
HIV Infections
Immunosenescence
Immune System
Immunity
Infection
Population

Cite this

Immunosenescence and hurdles in the clinical management of older HIV-patients. / Ripa, M; Chiappetta, S; Tambussi, G.

In: Virulence, Vol. 8, No. 5, 2017, p. 508-528.

Research output: Contribution to journalArticle

Ripa, M ; Chiappetta, S ; Tambussi, G. / Immunosenescence and hurdles in the clinical management of older HIV-patients. In: Virulence. 2017 ; Vol. 8, No. 5. pp. 508-528.
@article{041d3bac200b464d9ffd3bb9bd2f1c19,
title = "Immunosenescence and hurdles in the clinical management of older HIV-patients",
abstract = "People living with HIV (PLWH) who are treated with effective highly active antiretroviral therapy (HAART) have a similar life expectancy to the general population. Moreover, an increasing proportion of new HIV diagnoses are made in people older than 50 y. The number of older HIV-infected patients is thus constantly growing and it is expected that by 2030 around 70{\%} of PLWH will be more than 50 y old. On the other hand, HIV infection itself is responsible for accelerated immunosenescence, a progressive decline of immune system function in both the adaptive and the innate arm, which impairs the ability of an individual to respond to infections and to give rise to long-term immunity; furthermore, older patients tend to have a worse immunological response to HAART. In this review we focus on the pathogenesis of HIV-induced immunosenescence and on the clinical management of older HIV-infected patients. {\circledC} 2017 Taylor & Francis",
author = "M Ripa and S Chiappetta and G Tambussi",
year = "2017",
doi = "10.1080/21505594.2017.1292197",
language = "English",
volume = "8",
pages = "508--528",
journal = "Virulence",
issn = "2150-5594",
publisher = "Landes Bioscience",
number = "5",

}

TY - JOUR

T1 - Immunosenescence and hurdles in the clinical management of older HIV-patients

AU - Ripa, M

AU - Chiappetta, S

AU - Tambussi, G

PY - 2017

Y1 - 2017

N2 - People living with HIV (PLWH) who are treated with effective highly active antiretroviral therapy (HAART) have a similar life expectancy to the general population. Moreover, an increasing proportion of new HIV diagnoses are made in people older than 50 y. The number of older HIV-infected patients is thus constantly growing and it is expected that by 2030 around 70% of PLWH will be more than 50 y old. On the other hand, HIV infection itself is responsible for accelerated immunosenescence, a progressive decline of immune system function in both the adaptive and the innate arm, which impairs the ability of an individual to respond to infections and to give rise to long-term immunity; furthermore, older patients tend to have a worse immunological response to HAART. In this review we focus on the pathogenesis of HIV-induced immunosenescence and on the clinical management of older HIV-infected patients. © 2017 Taylor & Francis

AB - People living with HIV (PLWH) who are treated with effective highly active antiretroviral therapy (HAART) have a similar life expectancy to the general population. Moreover, an increasing proportion of new HIV diagnoses are made in people older than 50 y. The number of older HIV-infected patients is thus constantly growing and it is expected that by 2030 around 70% of PLWH will be more than 50 y old. On the other hand, HIV infection itself is responsible for accelerated immunosenescence, a progressive decline of immune system function in both the adaptive and the innate arm, which impairs the ability of an individual to respond to infections and to give rise to long-term immunity; furthermore, older patients tend to have a worse immunological response to HAART. In this review we focus on the pathogenesis of HIV-induced immunosenescence and on the clinical management of older HIV-infected patients. © 2017 Taylor & Francis

U2 - 10.1080/21505594.2017.1292197

DO - 10.1080/21505594.2017.1292197

M3 - Article

VL - 8

SP - 508

EP - 528

JO - Virulence

JF - Virulence

SN - 2150-5594

IS - 5

ER -